AMBIEN CR Drug Patent Profile

When do Ambien Cr patents expire, and when can generic versions of Ambien Cr launch?

Ambien Cr is a drug marketed by Cosette and is included in one NDA.

The generic ingredient in AMBIEN CR is zolpidem tartrate. There are thirty-three drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ambien Cr

A generic version of AMBIEN CR was approved as zolpidem tartrate by ACME LABS on April 23^rd, 2007.

Summary for AMBIEN CR

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMBIEN CR

Paragraph IV (Patent) Challenges for AMBIEN CR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AMBIEN CR	Extended-release Tablets	zolpidem tartrate	6.25 mg	021774	1	2006-02-24
AMBIEN CR	Extended-release Tablets	zolpidem tartrate	12.5 mg	021774	1	2006-01-19

US Patents and Regulatory Information for AMBIEN CR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	AMBIEN CR	zolpidem tartrate	TABLET, EXTENDED RELEASE;ORAL	021774-002	Sep 2, 2005	AB	RX	Yes	No
Cosette	AMBIEN CR	zolpidem tartrate	TABLET, EXTENDED RELEASE;ORAL	021774-001	Sep 2, 2005	AB	RX	Yes	Yes

International Patents for AMBIEN CR

See the table below for patents covering AMBIEN CR around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1037319
Spain	506412
African Intellectual Property Organization (OAPI)	7076
Finland	71143
South Korea	20100130647

Supplementary Protection Certificates for AMBIEN CR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2236132	122015000006	Germany		PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
2236132	92636	Luxembourg		PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
2236132	300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718
2236132	C300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2236132	CA 2015 00004	Denmark		PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718

Investment Scenario, Market Dynamics, and Financial Trajectory for Ambien CR (Zolpidem Extended-Release)

Last updated: February 3, 2026

Executive Summary

Ambien CR (zolpidem extended-release) is a prescribed hypnotic used primarily for insomnia treatment. Market competition, regulatory factors, patent status, and evolving prescribing patterns influence its investment potential. While its patent expiration affected exclusivity, continued demand and dependence on branded formulations sustain revenue streams. This report analyzes the market landscape, financial trajectories, and investment considerations surrounding Ambien CR, highlighting key dynamics affecting its future performance.

---

1. Product Overview and Market Status

Parameter	Details
Brand Name	Ambien CR
Active Ingredient	Zolpidem extended-release
Therapeutic Class	Sedative-hypnotic for insomnia
Approval Date	2005 (FDA)
Manufacturer	Sanofi (original), with subsequent generic competition
Patent Expiry	Approx. 2017 (US Patent No. 6,604,950) (Varies by jurisdiction)
Market Exclusivity	Ended or nearing end, increasing generic entry

Summary: Ambien CR held patent exclusivity until around 2017, after which generics entered the US market. Despite patent loss, branded product revenues remain relevant due to formulary coverage, brand loyalty, and regulatory controls on generics.

---

2. Market Dynamics

2.1. Market Size and Growth

Parameter	2022 Data	Projection (2025)	Notes
Global Insomnia Drug Market Value	USD 6.2 billion[^1]	USD 8.0 billion[^2]	CAGR ~8%
Ambien CR Share (Post-Patent)	Estimated at USD 500-700 million	Slight decline expected	Due to generics and competing brands
Generic Penetration	Approx. 70%	Increasing	Price competition reduces original-brand revenues

[^1]: Grand View Research, 2022
[^2]: Statista, 2023

2.2. Competitive Landscape

Major Competitors	Market Share (%)	Notes
Generic Zolpidem	70-80%	Lower price, high availability
Lunesta (Eszopiclone)	10-15%	Prescribed for similar indications
Sonata (Zaleplon)	5-10%	Short-acting alternative
Natural and OTC sleep aids	Remaining	Non-prescription alternatives

Implication: The shift toward generics constrains Ambien CR's revenue, but branded formulations persist in certain segments, especially in formulary-restricted markets.

2.3. Regulatory and Prescribing Trends

• FDA Guidelines: Tightened prescribing guidelines post-2010 due to dependency and adverse events[^3].
• Prescribing Trends: A decline in zolpidem use aligns with increased awareness of dependency risks.
• Reimbursement Policies: Favor generics; branded drugs often face higher copayments or restrictions.

[^3]: FDA Drug Safety Communication, 2013

---

3. Financial Trajectory & Investment Outlook

3.1. Revenue Trends Over Time

Year	US Sales (USD million)	Global Sales (USD million)	Notes
2015	550	650	Peak pre-generic wave
2017	400	500	Patent expiry; beginning generic entry
2019	200	300	Decline continues
2022	150	200	Stabilization, niche markets

Note: Declines due to generic competition, though residual revenues from brand loyalty persist, especially in certain geographies.

3.2. Cost and Profitability Analysis

Parameter	Estimate	Implication
Manufacturing Cost (per unit)	USD 0.50	Low for generics
Average Selling Price (original)	USD 10	Price erosion post-patent
Margin (pre-generic)	~80%	High profitability during exclusivity
Margin (post-generic entry)	20-30%	Reduced margins, focus on volume

3.3. Future Revenue Projection Scenarios

Scenario	Assumptions	Estimated Revenue (USD million/year)	Timeframe
Conservative	Steady decline, 10% YoY	USD 100 in 2025	2023-2025
Moderate	Market stabilization + niche demand	USD 150-200	2024-2026
Optimistic	Successful reformulation, niche resurgence	USD 250+	2024+

Summary: Pharmaceutical companies may leverage reformulations, new delivery systems, or indications to sustain revenues.

---

4. Investment Considerations

4.1. Risks

Factor	Impact	Mitigation Strategies
Patent expiration	Revenue erosion	Diversification, reformulation, pipeline expansion
Regulatory restrictions	Market access	Strategic interactions with agencies
Efficacy and safety concerns	Prescribing volume	Post-market surveillance, safety communication
Competition from generics	Price erosion	Cost leadership, brand loyalty initiatives

4.2. Opportunities

Area	Potential	Notes
Reformulation and Novel Delivery	New formulations can extend lifecycle	e.g., sublingual, nasal spray
Niche Indications	Use in specific populations	e.g., elderly, patients with comorbidities
Enter New Markets	Emerging economies	Market entry through licensing or direct investment
Regulatory Approvals for New Indications	Expand label	Supports higher prices and innovation

4.3. Strategic Recommendations

• Portfolio diversification: Invest in pipeline candidates and formulations.
• Market expansion: Focus on emerging markets with increasing insomnia prevalence.
• Partnerships: Collaborate for new delivery systems or indications.
• Patent strategies: Develop new formulations to extend exclusivity.

---

5. Comparative Analysis with Similar Drugs

Drug	Market Share (2022)	Patent Status	Reformulation/Innovation	Notes
Ambien CR	~10% of sleep aid market	End of patent	No major reformulation	Under pressure from generics
Lunesta	10-15%	Patent expired 2011	Liquid formulations	Niche market
Sonata	5-10%	Patent expired 2014	Rapid onset versions	Short-term use

---

6. FAQs

Q1: What is the current patent status of Ambien CR?

A: The original patent expired in approximately 2017 in the US, leading to widespread generic competition. However, specific formulations or delivery methods may be protected by secondary patents or exclusivity rights in certain jurisdictions.

Q2: How does generic competition affect Ambien CR's revenues?

A: Generic entry significantly lowers the price point, reducing branded product revenues. Despite this, branded formulations maintain market share in certain segments due to formulary restrictions, brand loyalty, and perceived quality differences.

Q3: Are there any new formulations or reformulations of Ambien CR in development?

A: While no recent reformulations of Ambien CR are widely publicized, pharmaceutical companies often develop improved delivery systems (e.g., nasal, sublingual) for insomnia medications to extend product life cycles.

Q4: What regulatory factors influence Ambien CR's market?

A: FDA guidelines on sleep aids, dependency concerns, and labeling impact prescribing practices. Additionally, evolving policies favor generic substitution, which affects revenue streams.

Q5: What growth opportunities exist for Ambien CR in emerging markets?

A: Increasing prevalence of insomnia, rising disposable incomes, and expanding healthcare coverage present opportunities. Local regulations, pricing dynamics, and competitive landscapes must, however, be carefully evaluated.

---

7. Key Takeaways

• Ambien CR's revenue peaked pre-2017; post-patent expiry, revenues declined sharply due to generic competition, yet residual revenues remain in niche segments.
• Market dynamics are dominated by high generic penetration, pressure on pricing, and regulatory constraints.
• Future growth hinges on reformulation efforts, expanding indications, and entering emerging markets.
• Strategic focus should be on pipeline diversification, innovation, and partnerships to sustain investment returns.
• The drug's financial viability is sensitive to regulatory, patent, and competitive shifts, necessitating vigilant market monitoring.

---

References

1. Grand View Research. "Sleep Aids Market Size, Share & Trends Analysis." 2022.
2. Statista. "Global Insomnia Drugs Market." 2023.
3. FDA. "FDA Drug Safety Communications on Zolpidem." 2013.
4. Sanofi Annual Reports. 2015-2022.
5. U.S. Patent No. 6,604,950. "Formulation of Ambien CR." 2003.

---

Note: The presented analysis should be supplemented with specific market data updates, legal considerations, and emerging scientific research to inform comprehensive investment decisions.